Wall Street brokerages predict that BioXcel Therapeutics Inc (NASDAQ:BTAI) will post ($0.34) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for BioXcel Therapeutics’ earnings. The firm is expected to issue its next earnings results on Friday, February 8th.

On average, analysts expect that BioXcel Therapeutics will report full-year earnings of ($1.20) per share for the current year. For the next fiscal year, analysts anticipate that the business will post earnings of ($2.03) per share. Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research firms that follow BioXcel Therapeutics.

BioXcel Therapeutics (NASDAQ:BTAI) last released its quarterly earnings results on Friday, November 9th. The company reported ($0.31) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.05).

Several research analysts recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 price target on shares of BioXcel Therapeutics in a research note on Wednesday, December 12th. Zacks Investment Research lowered BioXcel Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, December 11th. One research analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $18.67.

Shares of NASDAQ:BTAI traded down $0.16 during trading on Friday, hitting $7.67. The company’s stock had a trading volume of 850 shares, compared to its average volume of 47,248. BioXcel Therapeutics has a fifty-two week low of $2.41 and a fifty-two week high of $14.79.

In related news, Director Peter Mueller bought 8,795 shares of the stock in a transaction dated Friday, December 7th. The stock was bought at an average cost of $5.01 per share, with a total value of $44,062.95. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have bought 19,152 shares of company stock valued at $95,778 over the last ninety days.

Large investors have recently bought and sold shares of the company. Creative Planning acquired a new position in shares of BioXcel Therapeutics during the third quarter worth approximately $102,000. BlackRock Inc. acquired a new position in shares of BioXcel Therapeutics during the second quarter worth approximately $137,000. Finally, Artemis Investment Management LLP boosted its position in shares of BioXcel Therapeutics by 1.3% during the third quarter. Artemis Investment Management LLP now owns 1,254,853 shares of the company’s stock worth $9,700,000 after buying an additional 16,358 shares during the period. 20.79% of the stock is owned by institutional investors.

About BioXcel Therapeutics

BioXcel Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers.

Further Reading: Rule of 72

Get a free copy of the Zacks research report on BioXcel Therapeutics (BTAI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for BioXcel Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioXcel Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.